Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Sustained leadership position in the European modern insulin market European insulin market by segments Device penetration Modern Insulin penetration² tMU CAGR volume¹: 2.5% Penetration 180 CAGR value¹: 3.3% 100% 60% 160 50% 140 80% 120 40% Fast-acting 60% 100 30% 80 Premix 40% 60 20% 40 20% 20 Long-acting 10% 0 0% 0% Aug 2011 Aug 2016 1 CAGR for 5-year period 2 Includes new-generation insulin Source: IMS Monthly MAT August, 2016 volume and value (DKK) figures changing diabetes® Slide 47 European modern insulin³ volume market shares Novo Nordisk Sanofi Eli Lilly Aug 2011 3 Includes new-generation insulin Source: IMS Monthly MAT August, 2016 volume figures, numbers do not add up to 100% due to smaller insulin manufacturers 45% 35% 18% Aug 2016 novo nordisk

View entire presentation